心脏缺氧的正电子发射断层显像（PET）：直击缺氧痛点
PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts.
作者信息
Pell Victoria R, Baark Friedrich, Mota Filipa, Clark James E, Southworth Richard
机构信息
1School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
2School of Cardiovascular Medicine and Sciences, BHF Centre, King's College London, London, UK.
出版信息
Curr Cardiovasc Imaging Rep. 2018;11(3):7. doi: 10.1007/s12410-018-9447-3. Epub 2018 Feb 23.
PURPOSE OF REVIEW
In this review, we outline the potential for hypoxia imaging as a diagnostic and prognostic tool in cardiology. We describe the lead hypoxia PET radiotracers currently in development and propose a rationale for how they should most appropriately be screened and validated.
RECENT FINDINGS
While the majority of hypoxia imaging agents has been developed for oncology, the requirements for hypoxia imaging in cardiology are different. Recent work suggests that the bis(thiosemicarbazone) family of compounds may be capable of detecting the subtle degrees of hypoxia associated with cardiovascular syndromes, and that they have the potential to be "tuned" to provide different tracers for different applications.
SUMMARY
New tracers currently in development show significant promise for imaging evolving cardiovascular disease. Fundamental to their exploitation is their careful, considered validation and characterization so that the information they provide delivers the greatest prognostic insight achievable.
综述目的
在本综述中，我们概述了缺氧成像作为心脏病学诊断和预后工具的潜力。我们描述了目前正在研发的主要缺氧PET放射性示踪剂，并提出了关于如何最恰当地对它们进行筛选和验证的基本原理。
最新发现
虽然大多数缺氧成像剂是为肿瘤学开发的，但心脏病学中缺氧成像的要求有所不同。最近的研究表明，双（硫代半卡巴腙）类化合物可能能够检测与心血管综合征相关的细微缺氧程度，并且它们有可能被“调整”以提供适用于不同应用的不同示踪剂。
总结
目前正在研发的新型示踪剂在成像演变中的心血管疾病方面显示出巨大潜力。对它们进行有效利用的基础是对其进行仔细、周全的验证和特性描述，以便它们提供的信息能够带来可实现的最大预后洞察力。
Zotero 插件